SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-21-000180
Filing Date
2021-12-22
Accepted
2021-12-22 16:01:46
Documents
13
Period of Report
2021-12-17
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20211217.htm   iXBRL 8-K 39466
2 EX-3.1 exhibit31_rvncdec2021arbyl.htm EX-3.1 180958
  Complete submission text file 0001479290-21-000180.txt   397517

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20211217.xsd EX-101.SCH 1937
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20211217_lab.xml EX-101.LAB 25138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20211217_pre.xml EX-101.PRE 13077
7 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20211217_htm.xml XML 11839
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 211513212
SIC: 2834 Pharmaceutical Preparations